Purchase this article with an account.
S. Catalano, S. Abbruzzese, M. Rispoli; Combined Laser Prp and Intravitreal Bevacizumab in Eyes Affected by Proliferative Diabetic Retinophaty. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4229.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
to value the efficacy of the combined PRP + IVT therapy compared to the laser PRP therapy.
6 patients (a total of 12 eyes) affected by a bilateral proliferative diabetic retinophaty. Only one eye of each patient has been treated with a combined intravitreal bevacizumab injection of 0.125 mg and then, after 7 days a panretinic laser treatment in four sessions.The other eye has been treated only with the PRP laser. All the patients have been checked by a complete ophthalmological examination, OCT spectral domain of the 30° centrals, a FAG before and after the treatment.
As a consequence of the intravitreal injection, the patient’s eyes have reduced the vascular proliferations as diagnosed by the FAG in the 7th day and the laser PRP treatment has proved faster, with less energy and in a shorter period of time. The eyes treated with only PRP laser have required much time and most of all a great intensity of laser application. The regression speed of the neovascular proliferations as a result of the FAG has been lower than the one consequent upon the combined treatment. The visual acuity has been preserved at the end of each treatment.
even though the laser PRP treatment is the gold standard in the proliferative diabetic retinophaty, in the most aggressive cases the combined intravitreal bevacizumab and PRP has allowed us to complete the treatment quickly and with complete certainly.
This PDF is available to Subscribers Only